HOME >> MEDICINE >> NEWS
Targeted, oral agent Enzastaurin shows favorable results

The data presented were gathered from a multicenter Phase II study of enzastaurin as a second- or third-line treatment of NSCLC (ASCO Abstract #7543 ). The rationale for the study was based on en-zastaurins unique mechanism of action as a serine/threonine kinase inhibitor, which is believed to suppress signaling through the PKC- and PI3K/AKT pathways. Historically, over-expression and ac-tivity of PKC- and PI3K/AKT have been associated with poor prognosis and treatment resistance in NSCLC. The primary objective of the study was progression-free survival at six months. Secondary endpoints were safety and overall survival at 12 months.

These data in NSCLC shed new light on the potential versatility of this agent, said Richard Gaynor, M.D., vice president, cancer research and global oncology platform leader for Lilly. Our objective with enzastaurin is to continue investigating the efficacy and safety of this unique molecule in order to determine the diseases where enzastaurin could have the most positive impact on patients.

In the study, patients received 500 mg of oral enzastaurin, once daily, until disease progression or un-acceptable toxicity occurred. In the 54 patients enrolled, the median progression-free survival was 1.9 months (95% Confidence Interval: 1.7-1.9) and the progression-free survival rate at six months was 14% (95% CI: 4.4%-23.6%). The median overall survival was 9.9 months (95% CI: 6.5-14.6). The overall survival rate at 12 months was 46.3% (95% CI: 32.1%-60.5%). The most common toxicity was fatigue. Additional toxicities observed included ataxia (n=1), thromboembolism (n=1), anemia (n=1) and dizziness.

Based on the encouraging survival and tolerability data gathered thus far, further evaluation of en-zastaurin in NSCLC, as a single agent or in combination, is warranted, said chief investigator for the study, Gerold Bepler, M.D., Ph.D., chief of thoracic oncology at the H. Lee Moffitt Cancer Center and Research In
'"/>

Contact: Neil Hochman
n.hochman@cprworldwideusa.com
212-453-2067
CPR Worldwide
2-Jun-2007


Page: 1 2

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. Studies suggest investigational agent reduces disease activity in MS
3. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
4. MRI contrast agent can detect heart attack in the making
5. Contrast agent puts new light on diagnosing breast cancer
6. New reagent delivers a chemical breakthrough at FSU
7. High-resolution imaging with contrast agent shows promise in osteoarthritis research
8. Study suggests anesthetic agent may have rapid antidepressant effects
9. Alzheimers medication shows promise in treating nerve agent and pesticide poisoning
10. Cranberries contain possible anti-caries/anti-plaque agents
11. New contrast agents may be on horizon for better medical imaging

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2018)... ... December 07, 2018 , ... ... critical juncture in world affairs, U.S. leadership and funding at the United Nations ... years—great strides in reducing extreme poverty and advancing global health plus meaningful reforms ...
(Date:12/6/2018)... RATON, Fla. (PRWEB) , ... December 06, 2018 ... ... those unable to cope with day-to-day life, there are alternative solutions. M.D.-formulated Relaxium ... , Relaxium Calm ’s main ingredient is Sensoril®, an extract of the ...
(Date:12/5/2018)... ... 2018 , ... Body by Ravi Plastic Surgery and Aesthetics ... to offer the BodyTitePRO treatment. Dr. Ravi Somayazula , practice founder, has ... noninvasive techniques to improve the face, breast and body. Together with his partner, ...
(Date:12/5/2018)... Ill. (PRWEB) , ... December 05, 2018 , ... ... CRO, FSP, Strategic Resourcing, and Consulting services, announced its new office location in ... will accommodate organic growth of clinical trial operations in Europe and additional in-country ...
(Date:12/5/2018)... ... December 05, 2018 , ... ... (HM). In this role, he will be responsible for the executive oversight of ... “We conducted an extensive, nationwide search for this position,” Tom Doran, president, HM ...
Breaking Medicine News(10 mins):
(Date:12/5/2018)... SIOUX FALLS, S.D. (PRWEB) , ... December 05, 2018 , ... ... of the inaugural $1 million Sanford Lorraine Cross Award. , Jean Bennett, M.D., ... an inherited form of blindness, accepted the award on Dec. 4 at Sanford Health, ...
(Date:11/29/2018)... HOLLYWOOD, Calif. (PRWEB) , ... November 29, 2018 , ... ... rehabilitation center located in North Hollywood, CA, announced today they were selected by ... California to participate in a new Volunteer Engagement Project. , The California Department ...
(Date:11/28/2018)... THE WOODLANDS, Texas (PRWEB) , ... November 28, ... ... from Rigaku Corporation has been published and is available to ... newsletter concentrating on single crystal X-ray diffraction, published by Rigaku Oxford Diffraction ...
Breaking Medicine Technology:
Cached News: